Cholesterol Drug Pelacarsen Fails to Affect Heart Health in Trials

In a surprising turn of events, the clinical trial for a hopeful cholesterol treatment, pelacarsen, yielded disappointing results, revealing no reduction in heart attacks or strokes among users. This outcome has left the scientific community reflecting on its implications for preventive cardiology.

The Horizon Trial Unveiled

Conducted with nearly 8,322 participants with elevated lipoprotein(a) — a genetic form of cholesterol linked to cardiovascular problems — the Horizon trial aimed to assess the efficacy of pelacarsen. Presented at the American Heart Association's annual conference, the results shocked many, including Dr. Amanda Doran from Vanderbilt University Medical Center, who was involved in the research.

Failures Despite Promising Cholesterol Reduction

Despite an impressive drop in lipoprotein(a) levels by 78% compared to a placebo, no corresponding decline in cardiovascular events emerged. Participants averaged 60 years of age and were monitored for around five years. Dr. Steven Nissen from the Cleveland Clinic, who led the trial, expressed astonishment at the unexpected neutral results, indicating that lower lipoprotein(a) levels did not yield the anticipated benefits.

Understanding the Lack of Efficacy

Various theories have surfaced to explain the trial's neutral outcomes. Dr. Karol Watson, a preventive cardiology expert from UCLA, suggested that beginning treatment later in life might limit its effectiveness because lipoprotein(a) levels are genetically predetermined from birth. Additionally, participants were also under rigorous treatment plans to manage other serious heart health indicators like LDL cholesterol and blood pressure, which could have masked any potential benefits of lowering lipoprotein(a).

Furthermore, many subjects were likely taking preventative medications, such as aspirin, which could have diminished the clot-related risks linked with high lipoprotein(a) levels. As Dr. Watson pointed out, the extent of the remaining risk was still uncertain within this thoroughly treated population.

The Importance of Lp(a) Testing

Despite the trial's disappointing results, the significance of lipoprotein(a) as a cardiovascular health risk marker remains unchanged. The American College of Cardiology and the American Heart Association recommend screening all adults for lipoprotein(a), given its fixed nature and long-term implications for heart disease identification. Dr. John Wilkins from Northwestern Medicine emphasized that the failure of pelacarsen does not erode the value of lipoprotein(a) as an important risk marker.

Individuals with high lipoprotein(a) readings still have a notable probability of cardiovascular events and should actively pursue preventive health measures.

Future Paths for Treatment

While pelacarsen may not have performed as hoped, enthusiasm continues for the development of alternative treatments targeting high lipoprotein(a). Ongoing trials for drugs like Eli Lilly’s lepodisiran and Amgen’s olpasiran, which work by inhibiting liver production of lipoprotein(a), may present more effective options. Moreover, innovative gene-editing technologies are also under exploration, with aims to eradicate the gene responsible for lipoprotein(a) production.

Dr. Doran remains optimistic: “We’re committed to finding solutions in the future.” The quest for effective treatment strategies continues, with researchers hopeful that advancements in cardiology will yield the results patients need.